CHA Vaccine Research Institute Co., Ltd – Trademark Portfolio

Entity Type: 99

CHA Vaccine Research Institute Co., Ltd holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include L-PAMPO and LIPO-PAM.

406ho 407ho, 560, Dunchon-daero, Jungwon

Seongnam-si Gyeonggi-do

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

LIPO-PAM
LIPO-PAM
Registered 2021
L-PAMPO
L-PAMPO
Registered 2021

Trademark Classifications

CHA Vaccine Research Institute Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does CHA Vaccine Research Institute Co., Ltd have?

CHA Vaccine Research Institute Co., Ltd has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does CHA Vaccine Research Institute Co., Ltd file in?

CHA Vaccine Research Institute Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CHA Vaccine Research Institute Co., Ltd's most well-known trademarks?

CHA Vaccine Research Institute Co., Ltd's registered trademark portfolio includes well-known marks such as L-PAMPO and LIPO-PAM. These are among 2 currently registered trademarks in the portfolio.

What is CHA Vaccine Research Institute Co., Ltd's trademark registration success rate?

CHA Vaccine Research Institute Co., Ltd has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.